Rajnish Nagarkar

Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India

Akash Khobragade, Suresh Bhate, Vijendra Ramaiah et al. · The Lancet · 2022 · 248 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

A Randomized Phase 2 Study of ADXS11-001 Listeria monocy'togenes-Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer

Partha Basu, Ajay Mehta, Minish Jain et al. · International Journal of Gynecological Cancer · 2018 · 178 citations · Full text

Medicine, Immunology, Oncology +17

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

Martin Schüler, James Chih‐Hsin Yang, K. Park et al. · Annals of Oncology · 2015 · 132 citations · Full text

Medicine, Oncology, Pharmacology +13

First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma

Sant P. Chawla, Zsuzsanna Pápai, Guzel Mukhametshina et al. · JAMA Oncology · 2015 · 106 citations · Full text

Medicine, Oncology, Pharmacology +11

Prevalence of Molecular Subtypes of Breast Cancer: A Single Institutional Experience of 2062 Patients

Prakash Pandit, Roshankumar Patil, Vijay Palwe et al. · European Journal of Breast Health · 2020 · 66 citations · Full text

Medicine, Oncology, Pathology +14